Clinical and Immunologic Evaluation of Dendritic Cell-Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma

Research and Development Division, Tella Inc, Tokyo, Japan.
Pancreas (Impact Factor: 2.96). 07/2011; 41(2):195-205. DOI: 10.1097/MPA.0b013e31822398c6
Source: PubMed


In the current study, we have evaluated the clinical and immunological responses in patients with advanced pancreatic carcinoma who received dendritic cell (DC)-based immunotherapy in combination with gemcitabine and/or S-1.
Dendritic cell-based immunotherapy (DC vaccine alone or DC vaccine plus lymphokine-activated killer [LAK] cell therapy) in combination with gemcitabine and/or S-1 has been carried out in 49 patients with inoperable pancreatic carcinoma refractory to standard treatment.
Of 49 patients, 2 patients had complete remission, 5 had partial remission, and 10 had stable disease. Prolongation of survival in this cohort was highly likely (median survival, 360 days). Survival of patients receiving DC vaccine and chemotherapy plus LAK cell therapy was longer than those receiving DC vaccine in combination with chemotherapy but no LAK cells. Increased numbers of cancer antigen-specific cytotoxic T cells and decreased regulatory T cells were observed in several patients on immunotherapy, but increased overall survival time tended to be associated only with the latter. None of the patients experienced grade 3 or worse adverse events during the treatment period.
Dendritic cell vaccine-based immunotherapy combined with chemotherapy was shown to be safe and possibly effective in patients with advanced pancreatic cancer refractory to standard treatment.

1 Follower
76 Reads
    • "Moreover, cyclophosphamide is toxic to immunosuppressive Treg cells and a metronomic regimen has been shown to improve anti-tumor cell response [81] [82] as well as cancer vaccine efficacy [83] [84] [85] [86] [87]. Similarly, gemcitabine selectively kills myeloid-derived suppressor cells (MDSCs) in vitro and in vivo [88], and has been tested in combination with cancer vaccines [89] [90] [91]. Docetaxel has been reported to modulate different cell subsets, enhancing CD8+ function and deleting Tregs [92] and has been evaluated in several human clinical trials to test the enhancement of immune response to cancer vaccine [93] [94]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT Hepatocellular carcinoma (HCC) is one of the five big killers worldwide and is frequently associated with chronic hepatitis B and C virus (HBV and HCV) infections. Tumor microenvironment consists of a complex network of cells and factors that plays a key role in the tumor progression and prognosis. This is true also for HCC. Several studies have shown strikingly strong correlation between HCC clinical prognosis and intratumoral infiltration of cells affecting tumor growth, invasion, angiogenesis and metastasis. None of such cells is yet validated for routine diagnostic and prognostic assessment. The present review aims at providing a state-of-the-art of such studies.
    Future Oncology 06/2015; 11(11):1591-8. DOI:10.2217/fon.15.39 · 2.48 Impact Factor
  • Source
    • "Mature DCs (mDCs) were generated under Good Manufacturing Practice conditions and cryopreserved in liquid nitrogen as described previously [5], with some modification. Briefly, a PBMC-rich fraction was obtained from the HSCT donor by means of leukapheresis with the use of the COM.TEC, cell separator (Fresenius Kabi Japan K.K., Tokyo, Japan). "
    [Show abstract] [Hide abstract]
    ABSTRACT: A 15-year-old girl with acute lymphoblastic leukemia received allogeneic dendritic cell vaccination, pulsed with Wilms tumor 1 (WT1) peptide, after her third hematopoietic stem cell transplantation (HSCT). The vaccines were generated from the third HSCT donor, who was her younger sister, age 12 years. The patient received 14 vaccines and had no graft-versus-host disease or systemic adverse effect, aside from grade 2 skin reaction at the injection site. WT1-specific immune responses were detected after vaccination by both WT1-tetramer analysis and enzyme-linked immunosorbent spot assay. This strategy may be safe, tolerable and even feasible for patients with a relapse after HSCT. Copyright © 2014 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.
    Cytotherapy 12/2014; 17(3). DOI:10.1016/j.jcyt.2014.10.003 · 3.29 Impact Factor
  • Source
    • "Serum CA125 levels were also evaluated to determine the peptide to be administered. Based on these results, DCs were prepared and pulsed with 1–3 synthesized peptides as previously described [18,19]. Briefly, peripheral blood mononuclear cells (PBMCs) were prepared from leukapheresis products by Ficoll-Hypaque gradient density centrifugation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Despite the increased rate of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and succumb to progressive disease. Dendritic cell (DC)-based immunotherapy has been developed as a novel strategy for generating antitumor immunity as part of cancer treatments. The present study aimed to assess the feasibility and clinical effects of DC therapy for recurrent ovarian cancer (ROC). Methods This retrospective study included 56 ROC patients who initially received standard chemotherapy followed by DC-based immunotherapy targeting synthesized peptides at 2 institutions between March 2007 and August 2013. The adverse events (AEs) and clinical responses were examined. Results No serious treatment-related AEs were observed. Seventy one percent of the enrolled patients developed an immunologic response. The median survival time (MST) from ROC diagnosis was 30.4 months, and that from the first vaccination was 14.5 months. Albumin levels of ≥4.0 g/dL and lactate dehydrogenase levels of <200 IU/L before vaccination were identified as significant independent factors by multivariate Cox proportional hazard analysis. The MST from the first vaccination in patients with albumin levels of ≥4.0 and <4.0 g/dL were 19.9 and 11.6 months, respectively. The corresponding disease control rates were 36% and 15%, respectively. Conclusions Our results demonstrated the feasibility and potential clinical effectiveness of DC-based immunotherapy for ROC patients. Additionally, a good nutritional status might be an important factor for further clinical effects.
    Journal of Ovarian Research 05/2014; 7(1):48. DOI:10.1186/1757-2215-7-48 · 2.43 Impact Factor
Show more